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Abstract
Objective: To present and discuss the treatment of autoimmune hemolytic anemia (AIHA). 
Materials and Methods: The medical records of all patients (n=19) diagnosed in a tertiary hematol-
ogy center between 1999 and 2010 were retrospectively reviewed.
Results: Median age at diagnosis of AIHA was 5 years (range: 4 months-17 years). In all, 13 patients had 
primary (idiopathic) AIHA, whereas 2 had primary Evans Syndrome (ES), 2 had autoimmune lymphop-
roliferative syndrome (ALPS)+ES, and 1 had Wiskott-Aldrich syndrome (WAS)+AIHA. Among the 13 
primary idiopathic AIHA patients, 9 recovered following a 4-8-week course of prednisolone treatment 
without relapses, whereas 3 patients required a longer course of prednisolone. One AIHA patient that was 
very resistant to prednisolone recovered after cyclosporine A was added to the treatment. All patients with 
primary idiopathic AIHA were in remission for a median of 3 years (range: 4 months-10 years) at the time 
this manuscript was written. Among the patients with primary ES, 2 had relapses similar to the ALPS 
patients. Splenectomy was performed in 1 primary ES patient, who at the time this report was written was 
also in remission. One ALPS patient required the addition of mycophenolate mofetil due to prednisolone 
resistance. The WAS patient was treatment resistant and died due to septicemia.
Conclusions: Primary AIHA in pediatric patients generally has an acute onset and good response to 
corticosteroids. Primary or secondary ES has a chronic or relapsing course, and treatment may require 
other immunosuppressive agents in addition to corticosteroids. Complications of splenectomy must 
not be underestimated in patients with underlying immunodeficiency. AIHA often causes considerable 
morbidity and mortality in WAS. (Turk J Hematol 2011; 28: 198-205)
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Özet
Amaç: Bu makalede otoimmün hemolitik anemi tedavisinin tartışılması amaçlanmıştır. 
Yöntemler ve Gereçler: Üçüncü basamak bir hematoloji merkezinde 10 yıl içinde tanı alan tüm otoim-Introduction
Autoimmune hemolytic anemia (AIHA) is char-
acterized by the production of antibodies directed 
against red blood cells (RBCs). These antigens initi-
ate RBC destruction via the complement and reticu-
loendothelial systems [1]. AIHA follows viral infec-
tion or vaccination more often in children than in 
adults [2]. Immunodeficiency or malignancy (espe-
cially malignancies of lymphoreticular tissues), sys-
temic lupus erythematosus (SLE), and other types 
of collagen vascular diseases are the most common 
causes  of  secondary  AIHA  in  children  [3].  Also 
some rare disorders such as giant cell hepatitis may 
cause AIHA [4].
Childhood AIHA often presents as an acute self-
limited  illness,  with  good  response  to  short-term 
steroid therapy in 80% of the patients [5]. In infants 
and adolescents onset can be insidious, with a ten-
dency to become chronic [6]. When there is under-
lying immune deficiency control of the hemolytic 
process  is  not  always  easy,  and  the  addition  of 
immunosuppressive drugs and splenectomy further 
increase the risk of severe infections and mortality. 
Although  corticosteroids  are  always  the  first-line 
therapy,  there  are  many  alternative  second  and 
third line treatments. AIHA is an uncommon condi-
tion;  treatment  responses  are  not  standard  and 
there is a lack of prospective controlled trials for 
determining  the  optimal  therapy.  Hematologists 
must individually tailor therapy for every chronic or 
unresponsive patient. Herein we present our experi-
ence with 19 pediatric and adolescent patients with 
AIHA and Evans syndrome (ES), and a discussion of 
treatment  options  in  the  light  of  the  literature  is 
reviewed. 
 
Materials and Methods
The medical records from a single tertiary pedi-
atric  hematology  center  that  was  established  in 
1999  were  retrospectively  reviewed.  All  patients 
with AIHA and ES that were diagnosed and/or fol-
lowed-up between 1999 and 2010 were included in 
the study. The study protocol was approved by the 
Kocaeli  University  Ethics  Committee.  Diagnoses 
were based on low-level hemoglobin, fragmented 
red cells, microspherocytes, polychromasia, macro-
cytosis,  nucleated  red  cells  on  peripheral  blood 
smear,  elevated  reticulocytes,  and  positive  direct 
Coombs test (IgG+C3). Age, gender, underlying dis-
ease associated with AIHA, complete blood counts, 
reticulocyte counts, Coombs test results, treatment 
drugs, splenectomy, treatment responses, relapses, 
and  follow-up  periods  were  recorded.  ES  was 
defined  as  the  combination  of  (either  simultane-
ously or sequentially) autoimmune hemolytic ane-
mia, immune thrombocytopenic purpura (ITP) and 
immune neutropenia. AIHA and ES were defined as 
the primary disease when there was no underlying 
disease, such as autoimmune lymphoproliferative 
syndrome  (ALPS),  congenital  immunodeficiency, 
common variable immunodeficiency, SLE, and lym-
phomas. 
Patients were treated with oral prednisolone 2-4 
mg/kg/day in 2-3 divided doses for 2-4 weeks, with 
tapering over another 2-6 weeks. If hematological 
mün hemolitik anemi olgularının (OİHA) (n=19) hastane kayıtları geriye dönük olarak incelenmiştir. 
Tanı sırasında ortanca yaş 5 (4 ay-17 yaş) tir. On üç hastada primer (idyopatik) OİHA, 3 hastada 
primer Evans Sendromu (ES), 2 hastada otoimmün lenfoproliferatif sendrom (OLPS) +ES, ve 1 has-
tada Wiskott-Aldrich sendromu (WAS) +OIHA saptanmıştır. On üç primer OİHA’li hastadan dokuzu 
4-8 haftalık prednizolon tedavisine cevap verirken ve nüks etmezken, üç hasta daha uzun süreli pred-
nizolon gerektirdi. Hastalardan biri prednizolona oldukça dirençliydi ve siklosporin A (CsA) ilavesiyle 
hemoliz kontrol altına alınabildi. Tüm primer OİHA’li hastalar ortalama 3 yıllık (4 ay-10 yıl) takipte 
remisyondaydı. Primer ES’lu hastaların ikisinde OİHA, OLPS’li hastalara benzer şekilde nükslerle 
seyretti. Primer ES’li hastaların birine splenektomi yapıldı ve halen remisyondadır. OLPS’li hastaların 
biri prednizolona ilave olarak dirençli OİHA nedeniyle mikofenolat mofetil de gerektirdi. WAS lı hasta 
dirençli OİHA atağı sırasında septisemi ile kaybedildi. 
Sonuç:  Çocukluk  çağında  primer  OİHA  genellikle  kortikosteroide  iyi  cevap  veren  akut  bir  seyir 
gösterirken,  primer  veya  sekonder  ES  nükslerle  giden  kronik  bir  seyir  gösterir  ve  tedavide  kor-
tikosteroidlere ilave olarak diğer immunosupresif ajanlar da gerekebilir. Altta yatan immün yetersizlik 
olduğunda splenektominin komplikasyonları göz ardı edilmemelidir. WAS’da OİHA kayda değer mor-
bidite ve mortalite nedenidir. (Turk J Hematol 2011; 28: 198-205)
Anahtar kelimeler: Otoimmün hemolitik anemi, Evans sendromu, çocukluk çağı, otoimmün lenfop-
roliferatif sendrom
Geliş tarihi: 23 Eylül 2010    Kabul tarihi: 05 Mart 2011
Sarper et al.
Autoimmune hemolytic anemia in children and adolescents Turk J Hematol 2011; 28: 198-205 199response  was  not  good,  prednisolone  30  mg/kg/
day was administered intravenously for 3 days. If 
the Hb level decreased during steroid tapering, the 
dose reverted to the preceding dose. Patients were 
also transfused with packed red cells if their Hb 
was  <7  g/dL.  Patients  were  defined  as  steroid 
responsive if the Hb level was stable or increased 
along with decreased reticulocyte count within 14 d 
of starting steroid treatment. 
Relapse was defined as a decrease in Hb while 
tapering steroid treatment or following discontinua-
tion of corticosteroids. Chronic AIHA was defined as 
symptoms  and  laboratory  abnormalities  persisting 
for >6 months. In unresponsive, steroid-dependent, 
and  relapsing  patients  cyclosporine  A  (CsA)  and, 
rarely, intravenous immunoglobulin (IVIG 1 g/kg/day 
for 2 d) or rituximab 375 mg/m2 weekly were tried as 
second-line  treatment.  In  patients  with  primary  or 
secondary ES corticosteroids and CsA were always 
administered, but mycophenolate mofetil (MM) 600 
mg/m2 b.i.d and azathioprine 3 mg/kg/day was also 
used  as  second-line  treatments.  Splenectomy  was 
performed in chronic AIHA and ES patients if there 
was no evidence of underlying immunodeficiency. In 
patients with chronic AIHA, ES, or lymphoprolifera-
tion,  history  of  frequent  infections,  growth  failure, 
and  eczema  or  any  other  autoimmune  disease 
serum  immunoglobulin  assay  and  flow  cytometric 
analysis of peripheral lymphocyte subsets and dou-
ble negative T cells (DNTC) were also performed.
 
Statistical methods
SSPS v.13.0 for Windows and descriptive statis-
tics  were  used  to  calculate  median  hemoglobin 
level, age, and follow-up period. 
 
Results
Between 1999 and 2010 we followed-up 19 AIHA 
and ES patients (14 male and 5 female). In all, 17 of 
the patients had warm autoantibodies and 2 patients 
had negative Coombs test results. Patient character-
istics, management, and outcome are presented in 
the Table 1. Median age at diagnosis of AIHA was 5 
years (range: 4 months-17 years). In total, 7 (36.8 %) 
of the patients were <12 months of age when AIHA 
was diagnosed; 13 patients (patients 1-13) had pri-
mary (idiopathic) AIHA, whereas 3 had primary ES, 
2  had  ALPS+ES,  and  1  had  Wiskott-Aldrich  syn-
drome  (WAS)+AIHA.  Patients  with  ES  had  either 
sequential or simultaneous ITP . Median Hb concen-
tration at admission was 5.6 g/dL (range: 2.9-11.3g/
dL). Patient 7 was followed-up for neutropenia for 3 
months, followed by spontaneous recovery and the 
development of AIHA. Among the 5 patients with 
ES,  3  also  had  neutropenia.  All  neutropenia  and 
thrombocytopenia  responded  to  immunosuppres-
sive therapy at the same time anemia did. All the 
patients,  except  patients  6,  7,  and  13,  received 
packed  red  cells  in  addition  to  prednisolone  at 
admission. Intravenous prednisolone was adminis-
tered to infants during initial therapy due to inges-
tion problems. Generally, there was incompatibility 
during  cross-matching.  The  least  reactive  packed 
red cells were transfused, and no severe hemolytic 
reactions attributable to transfusion were observed; 
however, patient 2 was previously typed as AB Rh 
positive at another center and the patient was trans-
fused twice with AB Rh-positive packed red cells. 
Transfusion  increased  hemolysis.  The  patient’s 
actual blood type was not known prior to admis-
sion.  Transfusion  with  O  Rh-negative  packed  red 
cells did not cause any hemolytic reaction and the 
patient was correctly typed as O Rh positive.
In all, 9 of the 13 primary idiopathic AIHA patients 
recovered following a 4-8-week course of predniso-
lone  2-4  mg/kg/day  without  relapses,  whereas  3 
patients required a longer course of prednisolone 
treatment (patients 2, 6, and 8 due to relapse during 
prednisolone tapering). Patient 2 received low-dose 
prednisolone (0.5 mg/kg/day) for 20 months to con-
trol hemolysis. In total, 12 patients exhibited rapid 
response to prednisolone, but patient 12 was very 
resistant to prednisolone and responded after CsA 
was added to the treatment (started at a dose of 6 
mg/kg/day, with a target blood level of 200 ng/mL 
with monitoring). Patient 12 was also treated with 
IVIG 1 mg/kg/day for 2 d, and rituximab 375 mg m-2 
QWK (only 2 doses were available due to off-label 
administration)  was  administered  in  an  effort  to 
discontinue CsA, but CsA dependence persisted for 
13 months, after which time it was discontinued. All 
primary idiopathic AIHA patients were in remission 
for a median of 3 years (range: 4 months-10 years) 
at the time this report was written. 
Among  the  patients  with  primary  ES,  3  had 
relapses or chronic cytopenias. Relapses in patients 
14 and 16 were controlled with 4-6-week courses of 
prednisolone, whereas patient 15 required CsA due 
to dependence on corticosteroids. Patient 14 had 3 
AIHA attacks in 3 years, including AIHA-associated 
thrombocytopenia during the last attack. Patient 15 
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Table 1. Characteristics, management, and outcome in the patients with AIHA and ES
Patients  Age at first  Hb  Reticulocyte  *PLT  Coombs  Underlying  Relapse  Drugs  Follow-up  Outcome
  AIHA attack,   (g/dL)  (%)  count/  test  disease    treatment  duration
  gender    absolute  ANC        duration  after first
                  AIHA attack
1  4 months, M  4.4   25  N/N  +  No  No   Pred.  10 years  remission
      ND          5 weeks   10 years
2   9 months, F  3.3  1.2  N/N  +  No  3 relapses  Pred., IVIG  11 years  remission
      ND           26 month    9 years
                (maintenance) 
3   11 months, M  5.5  23  N/N  –  No  No  Pred.  5 years  remission
      ND          8 weeks    5 years
4   16 years, M  5.6  11  N/N  +  No  No  Pred.  5 years  remission
      ND          8 weeks    5 years
5   2 years, F  6.2  4  N/N  +  No  No  Pred.  14 months  remission
      128,000          8 weeks    12 months
6   8 years, M  9.3  8.4  N/N  +  No  No  Pred.  3.8 years  remission
      274,000          16 weeks    3.5 years
7   6 months, M  7.7  0.44   N/L  –/+  No  No  Pred.   3.5 years  remission
      25,300          8 weeks    3.3 years
8   9 months, F  3.7  15  N/N  +  No  1 relapse  Pred.  2 years  remission
      288,000          16 weeks    20 months
9   11 years, M  5.6  27.1   N/N  +  No  No  Pred.  11 months  remission
      871,000          4 weeks    10 months
10   9 months, F  4.1  2.29  N/N  –  No  No  Pred.   18 months  remission
      75,000          4 weeks    17 months
11   5 years, M  6.5  18.2  N/N  +  No  No  Pred.  3.1 years  remission
      424,000          4 weeks    3 years
12   4 months, F  2.9  1.72   N/N  +  No  No  Pred.   3 years  remission
      ND          IVIG     2 years
                CsA
                Rituximab
                13 months 
13   13 years, M  11.3  1.39  N/N  +  No  No  Pred  9 months  remission
                4 weeks    8 months 
14   3 years, M  3  9  L/N   +  Primary  3 relapses  3 Pred.   3.1 years  last
      248 700      Evans    courses    remission
                within     4 months
                3 years  
15  15 years, M  6.8  3.5  L/L  +  Primary  No  Pred.,  2.3 years  Remission
            Evans    CsA     20 months
                8 months    postsplenectomy
                Splenectomy    14 months
16  17 years, M  6.6  4.2  L/L  +  Primary  2 relapses  2 Pred.   3.1 years  Remission
            Evans    courses    2.5 years
                within 
                3 years 
17   10 years, M  5.2  18  N/L  +  ALPS  multiple  Pred.   5.2 years  Remission
            Evans  relapses  Deflazacort    4.5 years
                MM
                9 months 
†18  7 years, M  7  25  N/N  +  ALPS  3 relapses  Pred.  13 years  remission
            Evans    ND    2 years
19   5 years, M  3.7  0.7  L/N  +  WAS  Resistant  Pred.  50 days  Eksitus
              attack   5 weeks,    Septicemia
                CsA 4 weeks    50 days
                IVIG
                Azathioprine
                50 days 
ANC: Absolute neutrophil count; PLT: platelets; N: normal; L: low
*Normal values: PLT: 150,000-450,000 mm3; ANC: >1000 mm3 for infants and >1500 mm3 for children >1 year of age
Coombs test=direct anti-globulin test; CsA: cyclosporin A; MM: mycophenolate mofetil; †: followed-up elsewhere in the past; IVIG: intravenous immunoglobulin; ND: not definedpresented with ITP at the age of 3 years and was 
previously treated with several courses of IVIG at 
other centers. On his admission to our center he 
had a history of chronic ITP and neutropenia. He 
had perianal and oral lesions (3-4 attacks yearly). 
We  administered  a  10-d  course  of  antibiotics  for 
each  attack.  Immunoglobulin  levels  were  within 
normal levels during follow-up in our center. He did 
not have other infections indicative of immunodefi-
ciency. When he was fifteen, he had an AIHA attack. 
The  following  year  AIHA,  thrombocytopenia,  and 
neutropenia were in remission following CsA treat-
ment and he underwent splenectomy; 14 months 
post-splenectomy he no longer had cytopenias or 
oral/  perianal  infections.  Patient  16  presented  as 
chronic  ITP  with  remissions  and  relapses,  and 
responded to short-course prednisolone. When he 
was 17 years old he suffered 2 moderate attacks of 
AIHA that responded to short-course prednisolone. 
He had eczema, and low-level IgA and IgM, but no 
history  of  recurrent  infections.  At  the  time  this 
report was written he was 20 years old and in remis-
sion. In his family history, there was a sister with ITP . 
Patient  17  had  ALPS  (severe  eczema,  asthma, 
splenomegaly,  lymphadenopathy,  DNTCS  7%)+ES 
and multiple relapses within a 9-month period: the 
patient presented with a very resistant, but finally 
prednisolone-dependent  disease  course.  During 
maintenance treatment prednisolone was replaced 
by  deflazacort  to  minimize  adverse  effects. 
Considering that 6 mg of deflazacort has approxi-
mately the same anti-inflammatory potency as 5 mg 
of prednisolone or prednisone, the patient received 
deflazacort  0.25  mg/kg/day  during  maintenance. 
MM 600 mg/m2 b.i.d was also added to the treat-
ment. The patient’s parents did not consent to off-
label use of rituximab. We recommended mainte-
nance  with  MM  to  this  patient  after  recovery  of 
cytopenias, but his compliance with treatment was 
poor. This patient’s autoimmune cytopenias were in 
remission for 4.5 years at the time this report was 
written. Patient 18 had ALPS (DNTS 6.3%)+ ES and 
was previously diagnosed and followed-up at a dif-
ferent hematology center. The patient had 3 relaps-
es in a 13 year-period, which were managed with 
prednisolone; as of the time this report was written 
he was in remission. He had low-level IgA and IgM. 
Patient 19, who was followed-up for WAS (congeni-
tal thrombocytopenia with small platelets, eczema, 
frequent infections, and absence of WAS protein), 
developed  AIHA  at  the  age  of  5  years.  Treatment 
began with prednisolone 4 mg/kg and increased to 9 
mg/kg on the second day due to severe hemolysis. 
On the 4th day of treatment CsA 6 mg/kg/day was 
also  administered  to  control  hemolysis  and  pred-
nisolone was decreased to 4 mg/kg/day. To control 
hemolysis, on day 9 azothiopurin 3 mg/kg/day was 
also administered but withdrawn on day 12 because 
it  was  ineffective.  The  patient’s  hemoglobin  was 
stable  on  day  15  with  prednisolon  and  CsA. 
Prednisolon was decreased to 3 mg/kg/day on day 
20  but  on  day  27  hemoglobin  began  to  decrease 
although the patient was on prednisolon and CsA. 
The patient required 15 packed red cell transfusions; 
he died due to septicemia on day 50 even though 
antimicrobial agents were administered for 12 d.
Discussion
The clinical pattern of childhood AIHA in 70%-
80% of cases is predominantly acute transient-type 
lasting 3-6 months, which is similar to that observed 
in 11 of the 13 patients (84%) in the present study 
with primary idiopathic AIHA that responded to a 
prednisolone  course  of  only  4-8  weeks.  As  previ-
ously  reported,  the  presented  patients  generally 
showed some improvement within 1 week of treat-
ment onset [1].
The direct Coombs test (warm antibodies) was 
initially negative in 3 of the presented patients, but 
was  subsequently  positive  in  1;  all  had  a  good 
response to prednisolone. Direct Coombs test results 
were reported as false negative in 2%-4% of cases 
[7]; this may be due to a low level of antibodies on 
red blood cells or low sensitivity of the test [8]. 
Some of the presented patients had reticulocyto-
penia. The cause of reticulocytopenia in AIHA is not 
well known. Reticulocytopenia might be indicative 
of  concomitant  accelerated  immune-mediated 
destruction  or  autoantibody-induced  apoptosis  of 
RBC  precursors  in  the  bone  marrow,  temporary 
suppression of bone marrow activity secondary to 
infection, and/or delayed bone marrow response to 
hemolytic events [9,10]. 
Transfusion can be difficult in AIHA patients due 
to  difficulty  in  finding  serocompatible  blood.  Pan 
agglutinating  warm  autoantibodies  complicate 
cross-matching.  A  panreactive  autoantibody  can 
mask an existing alloantibody by making all donor 
units appear cross-match incompatible. It is best to 
use blood of the same ABO and Rh group with the 
least incompatibility [11]. Packed red cells should 
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tored for signs of hemolytic reactions [12]. In the 
present  study  16  patients  presented  with  acute 
hemolysis that could not be hemodynamically com-
pensated  and  we  had  to  perform  transfusions. 
Following the above principals we did not observe 
transfusion-related hemolysis, except in patient 2, in 
whom blood typing was troublesome due to AIHA.
Some steroid-dependent patients, such as patient 
2, may require maintenance with low-dose cortico-
steroids  for  an  extended  period  [13].  In  patients 
dependent  on  high  daily  doses  (prednisolone   
>0.5 mg/kg) or in corticosteroid-refractory patients, 
cyclosporine  should  be  tried  before  rituximab, 
cyclophosphamide, or splenectomy [5]. In the pres-
ent study 1 patient with primary AIHA and 1 with 
primary ES required CsA. Two doses of rituximab 
were also administered to the AIHA patient, but its 
efficacy  could  not  be  determined  because  other 
drugs were also used. Rao et al. reported that 4 of 5 
pediatric patients with AIHA had complete response 
(no  response  in  1  patient)  after  4  doses  and  1 
patient had partial response after 6 doses of ritux-
imab during 18 months of follow-up [14]. 
One study reported an 83% overall response rate 
to mercaptopurine in children with refractory cyto-
penias  [15].  No  other  immunosuppressive  agents 
were required in the presented patients with pri-
mary AIHA.
Some researchers emphasized the exclusion of 
an underlying disease for the definition of true ES 
[16], whereas others defined secondary ES based 
on  underlying  disease;  we  agree  with  the  latter 
definition. ES is more than a coincidental combina-
tion of immune cytopenias; rather, it is a chronic 
state of profound dysregulation of the immune sys-
tem [17]. Despite discrepancies in descriptions, all 
researchers conclude that cytopenias are recurrent, 
often refractory to IVIG, corticosteroids, and sple-
nectomy, and that the syndrome may be fatal [18]. 
In very severe and refractory cases hematopoietic 
stem  cell  transplantation  (HSCT)  offers  long-term 
cure, but again carries the risk of severe morbidity 
and  transplant-related  mortality  [16].  The  present 
study  included  3  patients  with  primary  ES,  all  of 
whom had a chronic course. There is consensus 
concerning the first- and second-line therapies in 
ES, but the timing of splenectomy must be consid-
ered individually, so that the morbidity and mortality 
associated with the procedure can be justified. In 
patient 15 we planned splenectomy to prevent sub-
sequent attacks of AIHA and neutropenia-induced 
perianal infections, and to avoid the adverse effects 
of  corticosteroids  and  CsA,  and  absence  from 
school.  Prior  to  his  diagnosis  of  AIHA,  despite 
thrombocytopenia  he  did  not  have  any  bleeding 
and perianal infections rarely had a negative affect 
on his quality of life. In contrast to our observation, 
some researchers reported that the role of splenec-
tomy has never been established in ES and remis-
sions last only 1-2 months without support [16,18-
20].  In  a  survey  of  ES  mainly  from  the  US  and 
Canada  15  patients  underwent  splenectomy  at  a 
median age of 10 years (range: 1.2-26.5 years). The 
duration of response was 1 week-5 years, but medi-
an response was only 1 month [20].
Northon et al. evaluated the response to ritux-
imab in 8 pediatric patients (aged 0.3-16 years) with 
ES  from  the  literature  [16].  Seven  had  complete 
remission during a follow-up period of 12-15 months, 
but 2 had relapses and achieved a second complete 
remission with rituximab. Although we did not try 
rituximab  in  our  ES  patients,  the  results  seem 
encouraging and it may be worth trying before sple-
nectomy  [16].  Bader-Meunier  et  al.  also  reported 
successful  results  using  rituximab  therapy  in  ES. 
Complete or partial remission of at least one cyto-
penia was achieved in 13 of 17 patients (76%), and 
persisted in 11 with a mean follow-up of 2.4 years 
(range:  0.5-7  years).  Corticosteroid  therapy  was 
either stopped or tapered at 50%-100% of the base-
line dosage in all long-term responders. Moderate 
side effects and infection occurred only in 4 patients 
and  1  patient,  respectively.  They  suggested  that 
rituximab should be promptly proposed as second-
line treatment early in the course of pediatric ES 
refractory to steroids [21]. 
As in the presented patients, cytopenias may be 
sequential in ES. A second cytopenia may emerge 
over the course of 10 years [17]. Patient 14 presented 
with AIHA and also had ITP 3 years later. Patients 15 
and 16 had chronic ITP , followed by AIHA 12 and 11 
years later, respectively. In secondary ES underlying 
conditions may increase the risk of post-splenectomy 
sepsis and death. This procedure must be the last 
alternative after immunosuppressive treatments and 
rituximab have been tried. We did not perform sple-
nectomy in patients with ALPS. Even in patients with 
primary  ES  some  abnormalities  in  immunological 
studies have been reported. These abnormalities are 
hypogammaglobulinemia,  decreased  T-cell  num-
bers, and an elevated IgG level [22,23]. Patient 16 
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history of recurrent infections.
AIHA and ITP have been observed in 23%-51% of 
ALPS patients in different series, and autoimmune 
neutropenia  was  also  common  (19%-27%). 
Autoimmune  cytopenias  may  mark  the  clinical 
onset of the disease, even in the absence of signs of 
lymphoproliferation [24]. In patients diagnosed with 
ES laboratory work-up for ALPS is recommended. 
Markedly elevated DNTC (≥5%) was a strong predic-
tor of ALPS, whereas no patients with DNTC <2.5% 
had ALPS, based on apoptosis testing [25]. In the 
present series DNTC in the patients with ALPS was 
7%  and  6.3%.  Autoimmune  cytopenias  in  ALPS 
patients  are  often  severe  and  refractory  to  treat-
ment.  As  such,  splenectomy  has  frequently  been 
used  in  the  management  of  ALPS;  however,  this 
approach is associated with significant risk of sepsis. 
Successful results have been reported with MM and 
sirolimus. Use of rituximab, with the intent to ablate 
autoreactive B cells, has been associated with neu-
tropenia  and  persistent  hypogammaglobulinemia 
[23]. Cytopenias in ALPS patients do not respond to 
IVIG [26]. In 1 of the presented ALPS patients we 
used only prednisolone, but in ALPS patient 17 we 
used MM in addition to corticosteroids. In patient 17 
AIHA was severe and persisted for 9 months. 
In a recent review by Teachey et al. an algorithm 
for  the  treatment  of  ALPS  was  proposed. 
Prednisolone must be the first-line therapy in mod-
erate disease cases and MM must be the second-
line treatment if there is intolerance or refractori-
ness to prednisolone. In severe cases of disease, 
sirolimus may be added to prednisolone as first-line 
therapy.  In  patients  with  inadequate  response, 
refractory disease, or relapses, other agents, such 
as vincristine and methotrexate, are recommended 
as third-line treatment. Rituximab and splenectomy 
are considered fourth-line therapies [26].
In WAS the risk of developing an autoimmune 
disorder increases with age. Forty percent of males 
that survive the early complications of WAS develop 
one  or  more  autoimmune  conditions  [27].  AIHA 
always develops before the age of 5 years [28]. It 
was reported that 2 WAS patients had resolution of 
AIHA  after  rituximab  therapy,  but  1  relapsed  in  7 
weeks and the other underwent HSCT and was lost 
to  follow-up  [29].  When  long-term  survivors  of 
HSCT were evaluated 88% of HLA-identical and 38% 
of HLA-non-identical HSCT receivers exhibited nor-
mal autoimmunity [30]. The only curative therapy 
for WAS is early HSCT, even from alternative donors, 
before development of autoimmune complications 
and  severe  infections  [31].  Although  transplants 
from  HLA-matched  sibling  donors  have  the  best 
outcomes (81%-88% event-free survival), a matched 
unrelated  donor  also  should  be  considered  (71% 
event-free survival); results are best in patients <5 
years [32]. Chronic GVHD-independent autoimmu-
nity is observed in 20% of patients and is strongly 
associated with mixed/split chimerism status, sug-
gesting that residual host lymphocytes can mediate 
an autoimmune disease despite the coexistence of 
donor lymphocytes. Infectious complications relat-
ed to splenectomy are also significant and splenec-
tomy is not recommended prior to HSCT [30]. Other 
researchers also do not recommend splenectomy, 
which  was  commonly  performed  in  the  past  to 
increase platelet counts and reduce the risk of fatal 
hemorrhage [33]. For patients that cannot undergo 
HSCT short-term immunosuppression with steroids, 
and/or CsA and IVIG remain treatment of choise for 
control  of  autoimmune  cytopenias  with  carefull 
prophylaxis of infections.
Autoimmune complications are a cause of con-
siderable  morbidity  and  mortality  in  WAS  patients 
[34]. Cyclophosphamide and azathioprine was effec-
tive in some patients with AIHA, although all these 
patients  underwent  HSCT.  AIHA  has  never  been 
cured by immunosuppressive therapy. These treat-
ments are partially or transiently effective. HSCT is 
recommended as early as possible for patients with 
severe autoimmune complications [28]. A patient in 
the present study did not have a matched donor and 
died due to septicemia and resistant AIHA following 
immunosuppressive therapy. 
In conclusion, childhood primary AIHA generally 
has an acute onset that is responsive to 4-8 weeks 
of corticosteroid therapy. In patients with primary 
ES, the clinical course is chronic. Similarly, second-
ary  ES  in  ALPS  also  has  a  chronic  and  relapsing 
course. Treatment may require immunosuppressive 
treatment other than corticosteroids. Complications 
of  splenectomy  should  not  be  underestimated  in 
patients with underlying immunodeficiency. AIHA is 
associated with a high mortality rate in WAS patients 
and  HSCT  is  recommended  before  the  develop-
ment  of  autoimmune  cytopenias.  Treatment  of 
childhood  AIHA  must  be  individually  tailored  to 
patients and evidence of underlying disease must 
not be overlooked. 
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